Firebrick Pharma Expanded Nasodine Retail Strategy
The company moved to bring its nasal spray to U.S. pharmacy shelves following rapid online sales growth.
Updated on Sept. 29, 2026 in Healthcare
Live Poll
Do you trust the expansion plans of small-cap pharmaceutical companies into new retail markets?
Firebrick Pharma outlined plans in Q3 2026 to transition its Nasodine nasal spray from online-only sales to brick-and-mortar U.S. pharmacies. This move follows a period where online U.S. sales grew by more than 200% during the 2025-26 year.
Why it matters
The company is leveraging recent direct-to-consumer demand to secure physical distribution agreements, aiming to capture broader market share and steady cash flow. The strategy involves a multi-phased rollout intended to convert high digital interest into consistent retail turnover.
Firebrick reported U.S. online sales growth exceeding 200% for the 2025-26 year, with retail groups representing 700 stores expressing interest in stocking the product. The mothership will receive a 12% royalty and 20% manufacturing cost fee from the independent U.S. entity.
The players
Firebrick Pharma
An Australian pharmaceutical developer focused on nasal and throat spray products for global markets.
Al Moghaddam
The appointed lead for Firebrick Pharma's new standalone U.S. entity.
The details
Firebrick Pharma met with over 20 pharmacy chains in Boston to formalize a multi-phased distribution strategy. The company is establishing an independent U.S. entity to manage these retail partnerships and operations, signaling a departure from its current online-focused model. This approach allows the parent company to extract value through royalties and manufacturing fees while offloading the complexities of domestic logistics and retail management to a standalone firm.
Timeline
August 2026: Firebrick attended a pharmacy trade event in Boston.
2027: Planned timing for subsequent phases of the U.S. retail rollout.
Market Landscape
Firebrick's move reflects the broader industry trend where direct-to-consumer pharmaceutical brands use digital sales growth to negotiate physical retail distribution. This strategy mirrors other emerging health products that leverage initial online traction to prove demand before committing to the capital-heavy requirements of retail shelf space.
Operators in the pharmacy and retail supply chain should monitor the effectiveness of the company's multi-phased rollout and their selection of distribution partners. Watch for Firebrick to utilize its 12% royalty structure as a benchmark for evaluating future contract manufacturing agreements.
The takeaway
Retail expansion serves as a key signal that a digital-native product has achieved sufficient brand density to justify the overhead of brick-and-mortar logistics. Operators should track the rollout success in the 700 interested stores as a key performance indicator for the brand's U.S. viability.
Further reading
For broader trends in pharmaceutical distribution and market access, see Healthcare.
Source note: This article includes information reported by Stockhead.
Live Poll
Do you trust the expansion plans of small-cap pharmaceutical companies into new retail markets?
